Compare CVS Health Corp (CVS) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs S&P Global Inc — how do they compare? CVS Health Corp trades at $106.03 (market cap $135.12B), while S&P Global Inc trades at $439.8 (market cap $129.60B). The key difference: CVS Health Corp and S&P Global Inc are close in size by market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | SPGI | |
|---|---|---|
Market Cap | $135.12B | $129.60B |
Sector | Health | Financials |
52-Week High | $106.18 | $534.79 |
52-Week Low | $58.75 | $370.42 |
Enterprise Value | $201.66B | $141.57B |
Dividend Yield | 2.51% | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
S&P Global (SPGI) trades at $437.84, up 1.7% today, with a bullish technical outlook and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $15.34B and net income margin of 30.36%. Recent developments include the completion of the Mobility Global spinoff and a strategic shift toward AI-driven market intelligence solutions, positioning the company for sustained growth amid favorable debt issuance trends.
The outlook for SPGI is positive, driven by margin expansion targets and increasing API usage linked to AI adoption. Key risks include interest rate sensitivity in the ratings segment and competitive pressures. With 85.7% of analysts rating it a Buy and a consensus price target of $532.38, the stock offers significant upside potential, though investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
